BMK Pharma will establish a new 503B compounding pharmacy and CDMO facility in Allen, Texas, strengthening sterile drug production in the U.S
September 25, 2025 - BMK Pharma, founded by pharmaceutical entrepreneur Dr. Jay Bhaumik, has announced the establishment of its new U.S. headquarters in Allen, Texas. The 50,000-square-foot facility will serve as both a 503B compounding pharmacy and a sterile Contract Development and Manufacturing Organization (CDMO), producing injectable drugs and sterile dosage forms while supporting the pharmaceutical and biotech industries.
The facility, expected to open in Q3 2026, is a testament to BMK Pharma’s commitment to advancing Made in America prescription medications and strengthening the U.S. pharmaceutical supply chain. The new headquarters will create over 100 highly skilled jobs in Allen, ranging from automation engineers and chemists to pharmacists and scientific researchers.
“We are proud to launch BMK Pharma’s headquarters in Allen, Texas,” said Jay Bhaumik, President and Founder of BMK Pharma. “Our mission is to ensure a reliable and innovative supply of sterile medicines, developed and manufactured right here in the United States. Allen provides the perfect environment, with access to exceptional talent and a strong community that supports innovation.”
BMK Pharma chose Allen due to its business-friendly climate, highly educated workforce, and strategic support from the Allen Economic Development Corporation (AEDC). The collaboration with AEDC played a key role in making Allen the future home for BMK Pharma’s flagship operations.
“BMK Pharma’s decision to establish its headquarters here reflects Allen’s position as a growing hub for innovation and advanced manufacturing,” said Dan Bowman, President of Allen Economic Development Corporation. “This investment strengthens our local economy while reinforcing Allen’s reputation as a prime location for forward-thinking companies.”
In addition to pharmaceutical manufacturing, the facility will provide specialized expertise in sterile product development, partnering with pharmaceutical companies, biotech firms, and generic drug manufacturers. With a focus on innovation and quality, BMK Pharma aims to become a trusted partner in advancing drug development and manufacturing solutions.
The announcement comes at a time when securing domestic pharmaceutical production has become increasingly important. By investing in American-based facilities, BMK Pharma is positioned to help reduce supply chain vulnerabilities and ensure consistent access to critical medicines. The Allen headquarters represents a major milestone for BMK Pharma as it prepares for growth and innovation in the pharmaceutical sector.